Clinical Trial Update: Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating porfiromycin as adjuvant therapy with radiation in postoperative head and neck cancer patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Porfiromycin (porfiromycin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Head and Neck Neoplasms | Phase 3 | Status: TERMINATED